Evaluation of High Resolution Mass Spectrometry (HRMS) Acquisition Strategies for the Detection and Analysis of Illicit Drug Substances

Evaluation of HRMS Acquisition Strategies for Detection and Analysis of Illicit Drug Substances — Summary

Significance of the topic

Forensic toxicology increasingly requires analytical workflows that combine high sensitivity, confident compound identification and broad screening capability to detect both established drugs and emerging novel psychoactive substances. High-resolution mass spectrometry (HRMS) provides these attributes through accurate-mass measurement and flexible acquisition modes. Comparing targeted and data-independent HRMS acquisition strategies clarifies trade-offs between sensitivity, scope and retrospective data mining—information critical for laboratories choosing methods to meet routine casework, surveillance and discovery needs.

Objectives and overview of the study

The application study evaluated two HRMS acquisition strategies on a single Xevo MRT multi‑reflecting TOF platform: targeted Time-of-Flight Multiple Reaction Monitoring (Tof MRM) and data-independent MSE. The goals were to: characterize sensitivity (limits of detection), qualitative agreement in authentic urine specimens, and the practical advantages and limitations of each approach for routine forensic toxicology screening and confirmation.

Methodology and sample workflow

The experimental design used fortified urine calibration samples and authentic anonymized urine specimens. Key elements:

• Reference and calibration: Commercial system suitability standard diluted to 25 ng/mL; urine calibrators prepared by spiking pooled blank urine with 20 target analytes across 0.01–2500 ng/mL; authentic cohort of 20 urine samples plus a certified commercial DCT reference standard.
• Sample preparation: Simple dilution workflow — five-fold dilution of matrix with mobile phase A prior to analysis; demonstrated compatibility with dilution-only approaches.
• Chromatography and ionization: ACQUITY HSS C18 column, ESI positive mode, 15-minute gradient with ammonium formate (pH 3) as aqueous phase and acetonitrile with 0.1% formic acid as organic phase.
• Acquisition strategies: MSE (data-independent alternating low/high collision energy across the full mass range) for discovery and retrospective interrogation; Tof MRM (targeted quadrupole selection of predefined precursors and optimized product ion transitions) for enhanced sensitivity and specificity.

Použitá instrumentace (Instrumentation used)

• Xevo MRT Mass Spectrometer (multi-reflecting TOF) coupled to ACQUITY UPLC I-Class PLUS with Sample Manager - Flow Through Needle (SM-FTN).
• Chromatographic column: ACQUITY HSS C18.
• Software and data processing: waters_connect platform with UNIFI for MSE workflows and MS Quan Application for Tof MRM processing and automated QC checks (including mass-accuracy thresholds).

Main results and discussion

• Sensitivity: Targeted Tof MRM achieved substantially lower LODs (approximately 0.05–0.5 ng/mL across the monitored analytes), while MSE delivered LODs in the approximate range 0.5–5 ng/mL. This quantifies the expected sensitivity gain from targeted precursor selection and optimized transitions.
• Qualitative agreement: For analytes included in the targeted panel, both acquisition modes produced excellent agreement when applied to 20 authentic urine specimens, supporting the robustness of Tof MRM for routine targeted screening.
• Discovery and retrospective capabilities: MSE provided comprehensive full-spectrum precursor and fragment data (alternating low/high collision energy), enabling retrospective interrogation and identification of compounds beyond the target list. The study reported sub‑1 ppm mass accuracy and routine parts‑per‑billion level mass precision, enhancing confidence in non-target identifications.
• Representative example: Carfentanil detection by Tof MRM at an LOD of 0.05 ng/mL was demonstrated with consistent quantifier (m/z 395.23 > 335.21) and qualifier (m/z 395.23 > 246.15) transitions and a robust calibration profile in fortified urine.
• Reference urine standard: MSE analysis of the commercial DCT reference identified a broad concentration range of analytes (e.g., fentanyl at ~0.75 ng/mL up to codeine/dihydrocodeine at ~225 ng/mL), illustrating MSE's capacity to detect both low‑level and high‑abundance compounds within the same run.
• Operational trade-offs: Tof MRM reduces spectral complexity and improves signal-to-noise for trace analytes but is limited to preselected targets. MSE captures full-scan fragment information for broad surveillance and retrospective review but carries higher LODs and increased data-processing demands.

Benefits and practical applications

• Tof MRM: Optimal for targeted workflows requiring trace-level detection and quantitation (e.g., low‑abundance toxicants, confirmation panels, high-throughput screens with predefined analyte lists).
• MSE: Ideal for comprehensive screening, identification of unexpected or novel compounds, and retrospective data mining without reanalysis of samples.
• Combined platform advantage: Implementation on a single Xevo MRT instrument allows laboratories to deploy targeted and non-targeted workflows without additional hardware, balancing sensitivity with breadth.
• Informatics support: Integrated software (waters_connect/UNIFI/MS Quan) standardizes processing, enforces stringent mass-accuracy checks (precursor mass ≤ 2 ppm used in the study) and reduces operator dependence—making workflows reproducible and accessible to less experienced analysts.

Limitations and operational considerations

• MSE requires robust data processing infrastructure and spectral libraries to fully exploit retrospective and non-target identifications; spectral deconvolution can be computationally intensive.
• Tof MRM requires prior knowledge of targets and method development (optimized cone voltages and collision energies per transition), so it may miss emerging or unexpected substances not included in the panel.
• Choice of acquisition should be guided by laboratory priorities: sensitivity and routine quantitation favor Tof MRM; surveillance, discovery and retrospective needs favor MSE.

Future trends and potential applications

• Hybrid strategies and adaptive workflows: Laboratories are likely to adopt mixed approaches—routine screening with targeted panels complemented by periodic or case-driven MSE analyses to capture unexpected substances.
• Improved libraries and automated identification: Advances in spectral libraries for HRMS and machine‑learning assisted spectral matching will increase the reliability and speed of non-target identifications from MSE datasets.
• Streamlined sample preparation: Demonstrated compatibility with dilution-only workflows points to expanded high-throughput applications where minimal sample processing is desirable.
• Regulatory and forensic adoption: As HRMS platforms demonstrate sub-ppm mass accuracy and reliable quantitative performance, broader acceptance for confirmatory testing and courtroom evidence is anticipated, subject to validation and accreditation requirements.

Conclusion

The comparative evaluation shows that the Xevo MRT platform can support two complementary HRMS strategies: targeted Tof MRM for superior sensitivity and reliable quantitation of predefined analytes, and MSE for broad-spectrum discovery, retrospective interrogation and comprehensive screening. The primary trade-off is sensitivity versus analytical scope. Implementation decisions should reflect a laboratory’s case mix, throughput needs and investigative priorities. Combining both acquisition modes on a single HRMS instrument offers a flexible, future-proof solution for modern forensic toxicology.

Reference summary

The study supports and extends prior literature demonstrating HRMS (UPLC‑MSE/QTOF) utility for forensic screening and quantification, and provides applied performance data comparing targeted TOF MRM and MSE workflows on a next-generation MRT TOF instrument.

References

1. Rosano TG, Wood M, Ihenetu K, Swift TA. Drug Screening in Medical Examiner Casework by High-Resolution Mass Spectrometry (UPLC–MSE-TOF). Journal of Analytical Toxicology. 2013;37(8):1–14.
2. Dalsgaard P, et al. Quantitative Analysis and Screening of 30 Drugs in Whole Blood by SPE-UHPLC-TOFMS. Forensic Science and Criminology. 2013;1(1):1–6.
3. Bidny S, Gago K, Chung P, Albertyn D, Pasin D. Simultaneous Screening and Quantification of Basic, Neutral and Acidic Drugs in Blood Using UPLC-QTOF-MS. Journal of Analytical Toxicology. 2017;41(3):181–195.
4. Grapp M, Kaufmann C, Streit F, Binder L. Systematic Forensic Toxicological Analysis by Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry in Serum and Comparison to Gas Chromatography Mass Spectrometry. Forensic Science International. 2018;287:63–73.
5. Wood M, Barknowitz G, Goshawk JA, Lee R. Evaluation of Various TOF Acquisition Strategies for the Analysis of Illicit Drug Substances. Poster, 56th TIAFT Conference, Ghent, Belgium; 2018.
6. Mistry NS, Calton LJ, Cooper J. The Utility of MSE for Toxicology Screening with waters_connect and the Xevo G3 QTof Mass Spectrometer. Waters Application Note; 2023.
7. Mistry NS, Calton LJ, Cooper J. The Ultimate Forensic Toxicology Screening Companion—Xevo G3 QTof. Waters Application Note; 2023.
8. Mistry NS, Hammond G, Lieberman R, Starkie V. Forensic Toxicology Data-Independent Analysis Screening Using Xevo MRT Mass Spectrometer Delivering Routine Parts-per-Billion (ppb) Mass Accuracy. Waters Application Note; 2026.
9. Rosano TG, Ohouo PY, Wood M. Application of High Resolution UPLC-MSE/TOF for Confirmation in Forensic Urine Drug Screening by UPLC-MS/MS. Journal of Analytical Toxicology. In press.